Therapeutic Advances in Neurological Disorders

Therapeutic Advances in Neurological Disorders Q1区

  • 期刊收录:
  • SCIE
  • Scopus
  • DOAJ开放期刊
神经系统疾病的治疗进展杂志
  • ISSN:

    1756-2856

  • 影响因子:

    4.7

  • 是否综述期刊:

  • 是否预警:

    不在预警名单内

  • 是否OA:

  • jcr分区:

    Q1区

  • 发刊时间:

    2008

  • 发刊频率:

    Continuous publication

  • 中科院大类:

    医学

出版信息
  • 出版国家

    ENGLAND

  • 出版社:

    SAGE Publications Inc.

  • 数据库:

    SCIE,Scopus,DOAJ开放期刊

  • 年发文量:

    77

  • 国人发稿量:

    5.39

  • 自引率:

    -

  • 平均录取率:-
  • 平均审稿周期:15 Weeks
  • 版面费:$2,000 USD
  • 研究类文章占比75.32%
  • 被引用占比:100%
  • 偏重研究方向:CLINICAL NEUROLOGY-
杂志官网 投稿链接 关注公众号

期刊关键词

SCIEScopusDOAJ开放期刊CLINICAL NEUROLOGYQ1医学2区临床神经病学

期刊简介

Therapeutic Advances in Neurological Disorders delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of neurological conditions. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in neurology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.The editors welcome original research articles across all areas of neurology.The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a single-blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.

《神经疾病治疗进展》是一本同行评审、开放获取的期刊,提供关于神经病学所有领域的开创性努力和创新研究的最高质量的文章、评论和学术评论。该杂志以临床和药理学为重点,面向神经病学的临床医生和研究人员,为发表该领域最高质量的文章提供了一个印刷和在线论坛。

《Therapeutic Advances in Neurological Disorders》期刊已被查看:

期刊官网投稿信息

分区信息

中科院分区(2023年12月最新升级版)
  • 大类学科
  • 分区
  • 小类学科
  • 分区
  • Top期刊
  • 综述期刊
  • 医学
  • 2区
  • CLINICAL NEUROLOGY
    临床神经病学
  • 2区
JCR分区、WOS分区等级:Q1
  • 版本
  • 按学科
  • 分区
  • WOS期刊SCI分(2022-2023年最新版)
  • CLINICAL NEUROLOGY
  • Q1
IF值(影响因子)趋势图
年发文量趋势图
自引率趋势图
Cite Score趋势图

常见问题

《Therapeutic Advances in Neurological Disorders》同类:医学期刊